- Home
- LILA vs GYRE Comparison
LILA vs GYRE Comparison
Compare LILA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- GYRE
- Stock Information
- Founded
- LILA 2017
- GYRE 2002
- Country
- LILA Bermuda
- GYRE United States
- Employees
- LILA N/A
- GYRE N/A
- Industry
- LILA Cable & Other Pay Television Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- LILA Telecommunications
- GYRE Health Care
- Exchange
- LILA Nasdaq
- GYRE Nasdaq
- Market Cap
- LILA 1.1B
- GYRE 897.1M
- IPO Year
- LILA N/A
- GYRE N/A
- Fundamental
- Price
- LILA $4.91
- GYRE $9.07
- Analyst Decision
- LILA Buy
- GYRE
- Analyst Count
- LILA 2
- GYRE 0
- Target Price
- LILA $7.90
- GYRE N/A
- AVG Volume (30 Days)
- LILA 729.9K
- GYRE 337.8K
- Earning Date
- LILA 05-07-2025
- GYRE 05-09-2025
- Dividend Yield
- LILA N/A
- GYRE N/A
- EPS Growth
- LILA N/A
- GYRE N/A
- EPS
- LILA N/A
- GYRE 0.02
- Revenue
- LILA $4,441,000,000.00
- GYRE $100,643,000.00
- Revenue This Year
- LILA $3.30
- GYRE $22.01
- Revenue Next Year
- LILA $3.11
- GYRE $88.14
- P/E Ratio
- LILA N/A
- GYRE $112.98
- Revenue Growth
- LILA N/A
- GYRE N/A
- 52 Week Low
- LILA $4.26
- GYRE $6.11
- 52 Week High
- LILA $10.82
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- LILA 42.45
- GYRE 45.78
- Support Level
- LILA $4.83
- GYRE $9.26
- Resistance Level
- LILA $5.18
- GYRE $11.61
- Average True Range (ATR)
- LILA 0.24
- GYRE 1.09
- MACD
- LILA 0.02
- GYRE -0.21
- Stochastic Oscillator
- LILA 52.29
- GYRE 28.12
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.